|Biogen also manufactures and commercializes biosimilars of advanced biologics||To calculate, start with total shares outstanding and subtract the number of restricted shares|
|The all-or-none decisions represented by a futility analysis are sensible from a commercial perspective regarding how a company will fund further work||Biogen shares plummeted by 29% in March after the company said it would abandon the therapy following two failed clinical trials|
|For companies with multiple common share classes, market capitalization includes both classes||Shares Sold Short The total number of shares of a security that have been sold short and not yet repurchased|
|Biogen has announced that patients who had volunteered to take part in the trials, at some risk and trouble to themselves, should be able to take it again||The biotechnology company said it decided to revive the experimental therapy, called aducanumab, following a new analysis of data from two failed clinical trials and a series of discussions with the Food and Drug Administration|
|International stock quotes are delayed as per exchange requirements||Shares Outstanding Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public|
|Biogen will work towards this goal with regulatory authorities and principal investigators with a sense of urgency||By better I mean trials conducted among individuals at earlier stages of the disease, or among those with positive beta-amyloid scans or those who have elevated levels of another key protein, tau, in their cerebrospinal fluid|
|These studies were discontinued on March 21, 2019, following the results of a pre-specified futility analysis which relied on an earlier and smaller dataset||Shares of Cassava Sciences Inc|
|Overview page represent trading in all U||Sources: FactSet, Dow Jones Bonds: Bond quotes are updated in real-time|
|A new extensive analysis of this larger dataset showed a different outcome than the outcome predicted by the futility analysis||If you have any questions or encounter any issues in changing your default settings, please email|
|Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation, and language||Futility analyses are common in large clinical studies and use statistical modeling to attempt to predict the outcome of the studies based on a number of pre-specified assumptions and criteria|
The treatment was almost abandoned in March after its major clinical trial was written off as a failure — a development that sent shares plunging 29% in a single session.
You should not place undue reliance on these statements or the scientific data presented.
Since October 2017 Biogen and Eisai have collaborated on the development and commercialization of aducanumab globally.
Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper.
To learn more, please visit and follow us on social media — , , ,.
These statements are based on our current beliefs and expectations and speak only as of the date of this press release.
Change from Last Percentage change in short interest from the previous report to the most recent report.
Biogen also released somewhat controversial data about its late-stage Alzheimer's candidate at the conference on Thursday.
Source: FactSet Markets Diary: Data on U.
A similar thing has occurred with blood pressure drugs.
Build a discovery driven experience (push model)
Aggregate the long tail and drive discovery
Combining unexpected Services to create Awesomeness
Borchelt- Klain street no. 45, 75984 Hamilton, Bermuda
+37 207 644 937
Mon - Fri, 10:00-14:00